Related StoriesThermo Scientific Scientific launches HyPerforma SUM DS 300 system for multiple usesThermo Fisher Scientific launches Brilliance GBS AgarNew pre-validated fluorinated fragment library boosts drug screening efficiency Our agreement with AB SCIEX additional strengthens our position as the first choice in ambient ionization mass spectrometry systems, said Justin Wiseman, CEO and President of Prosolia.To explore the potential of APNT in treatment of ophthalmic diseases, Activus offers signed a collaboration contract with Professor Hifofumi Takeuchi and Professor Hideaki Hara of Gifu Pharmaceutical University and is currently working on the advancement of novel posterior eyesight segment medication. Posterior eyes segment disease such as diabetic retinopathy and age-related maculopathy may be the primary reason behind blindness and other visual impairments in middle age group. A highly effective and easy-to-use medication has not been invented still, and the development of a forward thinking treatment is usually anticipated. Within this subsidized project, Activus will be working on the development of novel ophthalmic solutions that would differ from the prevailing treatments because they would be sent to the posterior eyes segment.